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Abstract
Background: Although quite challenging, neuroprotective therapies in ischemic stroke remain an interesting strategy to
counter mechanisms of ischemic injury and reduce brain tissue damage. Among potential neuroprotective drug, cyclin-
dependent kinases (CDK) inhibitors represent interesting therapeutic candidates. Increasing evidence indisputably links cell
cycle CDKs and CDK5 to the pathogenesis of stroke. Although recent studies have demonstrated promising neuroprotective
efficacies of pharmacological CDK inhibitors in related animal models, none of them were however clinically relevant to
human treatment.
Methodology/Principal Findings: In the present study, we report that systemic delivery of (S)-roscovitine, a well known
inhibitor of mitotic CDKs and CDK5, was neuroprotective in a dose-dependent manner in two models of focal ischemia, as
recommended by STAIR guidelines. We show that (S)-roscovitine was able to cross the blood brain barrier. (S)-roscovitine
significant in vivo positive effect remained when the compound was systemically administered 2 hrs after the insult.
Moreover, we validate one of (S)-roscovitine in vivo target after ischemia. Cerebral increase of CDK5/p25 activity was
observed 3 hrs after the insult and prevented by systemic (S)-roscovitine administration. Our results show therefore that
roscovitine protects in vivo neurons possibly through CDK5 dependent mechanisms.
Conclusions/Significance: Altogether, our data bring new evidences for the further development of pharmacological CDK
inhibitors in stroke therapy.
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Introduction
Despite numerous clinical trials, neuroprotective therapies in
ischemic stroke have failed in human [1,2]. Protecting the brain
tissue from injury remains however an interesting, although quite
challenging, option in stroke treatment strategies [3]. It is indeed
widely accepted that not all brain cells die immediately after the
insult. Surrounding a core of severe and rapid tissue injury, brain
cell death spreads more slowly in a heterogeneous region called the
penumbra that could still be salvaged [4]. Numerous preclinical
studies have therefore shown that it is possible to achieve
significant reductions of ischemic injury using neuroprotective
strategies [5] but they failed later in clinical trials. Reasons for the
unsuccessful translation of neuroprotective therapies from animal
to human are probably multiple [6]. This has led the Stroke
Academic Industry Roundtable (STAIR) to make recommenda-
tions to improve the quality of preclinical studies of purported
acute stroke therapies [7,8]. One aspect concerns the preclinical
stage of the drug development where insufficient dose-response or
time-window studies, inappropriate drug delivery protocol, or
brain penetration issues are often encountered. In vivo analysis of
the mechanism targeted by the drug is also among the aspects that
should be improved.
Because excitotoxicity is a pivotal mechanism in ischemic
stroke, most of human trials in neuroprotection have focused on
glutamate release and glutamate receptor, but without success [5].
Such approaches targeted only the surface of the neurons. They
did not act along the transduction pathways involved in cellular
death nor on the extrinsic stressors associated with stroke, such as
activation of glial cells or inflammation. It became therefore
warranted that the ‘‘ideal’’ neuroprotective drug should display a
broad action mode by influencing concomitantly apoptotic,
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neurons, but also on astrocytes and oligodendrocytes.
Among potential neuroprotective drugs, cyclin-dependent
kinase (CDK) inhibitors represent interesting candidates to
overcome such a challenge. There is now abundant evidence that
the family of serine/threonine kinases CDKs have essential
functions in the apoptotic and excitotoxic pathways [9–11].
Within this cascade of events, CDK5 exerts a central role as a key
regulator of neuronal death and survival [11]. CDK5 is associated
with cerebral ischemia. CDK5 activity in the brain is triggered by
its binding partners p39 and p35 [12]. Deregulation of CDK5
under pathological conditions is induced by calpain- mediated
cleavage of p35 into a shorter form p25. The p25 fragment triggers
CDK5 hyperactivation and translocation of the p25/CDK5
complex to the cytoplasm where it hyperphosphorylates a number
of substrates, leading to neuronal death [13]. Moreover, up-
regulation of cell cycle proteins (cyclin D1, CDK4, and CDK2) is
associated with neuronal apoptosis, as well as proliferation and
activation of glial cells after cerebral ischemia [14–17].
Despite accumulating evidence that CDK5 and mitotic CDKs
may be essential targets for ischemic stroke, only few attempts to
modulate their in vivo activity have been reported so far [18–23].
Here we follow the STAIR recommendations to investigate the in
vivo neuroprotective potential of (S)-roscovitine, a well known
inhibitor of CDK5 and mitotic CDKs, in acute stroke. We show
that systemic delivery of (S)-roscovitine in the appropriate
formulation is neuroprotective in models of focal ischemia with
an appropriate therapeutic time window and cross the blood brain
barrier. We also show that (S)-roscovitine regulates CDK5 in vivo
activity after stroke, suggesting that CDK5 is involved in (S)-
roscovitine in vivo beneficial effect on ischemic brain.
Results
Systemic (S)-roscovitine protects from cell death in a
permanent model of focal cerebral ischemia
Although it has been established that (R)-roscovitine is able to
cross the blood brain barrier [24,25], its neuroprotective effect
after a systemic delivery route has never been reported in stroke
models. A systemic administration of the drug is moreover the only
feasible route of delivery in human stroke therapy. We therefore
investigated the beneficial effect of systemic (S)-roscovitine, the
levogyre form of roscovitine, in a model of permanent focal
ischemia in adult mice. This model consisted of the permanent
unilateral occlusion of the distal middle cerebral artery by
electrocoagulation (pMCAo; [26] modified from [27]). In this
model of distal occlusion, mice exhibit an ischemic lesion that is
exclusively ipsilateral and restricted to the temporoparietal cortex
[26]. The infarction is observed as early as 30 min after injury and
expands outwards to reach a maximum volume 24 hrs after
occlusion [26]. Preliminary characterization of the infarcted tissue
at 3 hrs after pMCAo using 2, 3, 5 tetrazolium chloride (TTC)
staining revealed a gradient of mitochondrial activity in the mouse
brain. In addition to the healthy peri-infarct region that displayed
a pink strong TTC staining, we observed two infarcted regions of
various TTC staining intensity: a white region of severely
decreased mitochondrial activity (called ‘‘ischemic core’’ by
Guegan and colleagues [26]), and a pinkish region of moderately
decreased mitochondrial activity representing a mitochondrial
hypometabolic area that cannot be assimilated to penumbra (also
called ‘‘ischemic zone’’ [26]) (Figure S1).
Using this model, we evaluated the neuroprotective effect of
systemic (S)-roscovitine on the ischemic volume in adult mice
brains 3 hrs after the onset of pMCAo (Figure 1A). Two
experiments using different delivery protocols of the compound
were performed. In the first set of experiment, the compound or its
vehicle control (n=5 mice per group) was first administered to the
animal intracerebroventricularly (ICV), via a micro-osmotic
pump, 48 hrs before the ischemic insult and throughout the
duration of the pMCAo, in order to validate (S)-roscovitine
beneficial effect. In the second set of experiment, the compound or
its vehicle control (n=5 mice per group) was delivered using 2
successive systemic (IP) injections at 15 min prior and 1 hr after
the occlusion. In this last experiment, animal body temperature
and blood glucose concentration were recorded during the surgical
procedure. No significant differences in these physiological
parameters were observed between the 2 experimental groups in
this experiment (Table S1). Hypothermia was observed for both
groups at 3 hrs post-occlusion despite heating procedures. No
significant difference was however observed between the 2 groups.
Ischemic core, ischemic hypometabolic zone and healthy area
were identified based on TTC- stained brain sections of vehicle-
(Figure 1B) and (S)-roscovitine- (Figure 1C) treated animals.
Analysis of the volume of each area revealed that (S)-roscovitine
treatment led to a 28% decrease of the total infarct volume
compared to vehicle-treated animals (Figure 1D). While similar
infarct volumes were measured in the ischemic core area both in
vehicle- and (S)-roscovitine- treated animals, a significant 36%
reduction of the ischemic zone volume was observed for the
animals treated with (S)-roscovitine in comparison to those which
received the vehicle only (Figure 1D). Similar observations were
made after systemic administration of (S)-roscovitine to the
animals with a 31% decrease of the total infarct volume
(Figure 1E). In this case, the volume of the ischemic zone was
significantly decreased by 39% in (S)-roscovitine- treated animals
compared to vehicle treated- animals (Figure 1E).
Development of injectable formulation for (S)-roscovitine
In order to establish a drug delivery protocol that is suitable for
human patient, we developed an injectable formulation for (S)-
roscovitine. Because of its low solubility at neutral pH (Table 1),
we screened for excipients that could increase (S)-roscovitine
solubility. Excipients selected in this study were surfactants
commercially available for human formulation [28]. Among the
formulations tested, we found that 30% hydroxypropyl b-
cyclodextrin (HPbCD) allowed the maximum solubilization of
the compound (Table 1). Blood brain barrier permeability of (S)-
roscovitine was therefore verified using this formulation. Our data
showed that exposure of the brain to (S)-roscovitine was
approximately 15% of that found in plasma of adult rat (Table 2).
Delayed treatment with systemic (S)-roscovitine provides
neuroprotection after transient focal cerebral ischemia
STAIR recommendations strongly suggest establishing a drug
efficacy both in permanent and transient models of acute stroke
and at least in 2 rodent species [7,8]. We therefore evaluated (S)-
roscovitine neuroprotective efficacy in a rat model of transient
focal ischemia that mimics more closely what happens in human
stroke, where recanalization occurs frequently. Moreover, in order
to validate the reproducibility of our data [8], 2 independent
blinded studies were therefore performed both at Neurokin and
MDS Pharma Services facilities using the model of transient
occlusion of the middle cerebral artery (tMCAo). In our first study,
transient focal ischemia was induced for 90 min in rats
(Figure 2A). (S)-roscovitine (n=16 rats) or its vehicle control
(n=18 rats) was administered by IV bolus at 15 min prior to
ischemia and by 3 successive SC injections performed at 15 min
prior and 24 and 29 hrs after the occlusion. Animals were
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temperature and blood glucose concentration were recorded
during the surgical procedures. A significantly lower temperature
was observed at the post-reperfusion time for the (S)-roscovitine
(pre-MCAo) group compared to the control one. Moreover, a
higher blood glucose concentration was observed at the post-
reperfusion time for the (S)-roscovitine group compared to the
control one (Table S2). Overall animal mortality in this study was
3%. No significant difference of animal mortality was observed
between the 2 experimental groups (p=0.31, Fisher exact test).
Analysis of the infarct volume at 48 hrs post-occlusion showed that
(S)-roscovitine significantly decreased by 30%, 33%, and 26%
respectively the total, cortical and sub-cortical volumes of the
infarcted regions in rats after 90 min of tMCAo (Figure 2B).
In our second set of experiments, tMCAo was induced for
120 min in rats (Figure 2C). (S)-roscovitine (n=11–12 rats) or its
vehicle control (n=13 rats) was administered by a IV bolus
immediately followed by continuous systemic (SC) infusion
performed either 15 min before (pre-MCA group) or 135 min
after (post-MCA groups) the ischemia onset were tested using of
the compound. In this last condition, various decreasing doses of
(S)-roscovitine were also tested. Animal body temperature and
blood glucose concentration were recorded during the surgical
procedures. If no significant differences in these physiological
parameters were observed for the animals that received the
compound after the ischemia onset (post-MCA groups), a higher
blood glucose concentration was observed at the post-reperfusion
Figure 1. Systemic (S)-roscovitine displays neuroprotective
efficacy in an adult mouse model of permanent MCAo. (A)
Scheme of the experimental protocol. Vehicle or (S)-roscovitine were
administered to pMCAo mice either by ICV infusion at a concentration
of 500 mM starting 48 hrs before pMCAo or by two intraperitoneal (IP)
injections at a dose of 25 mg/kg done 15 min pre- and 1 hr post-MCAo.
Animals were sacrificed at 3 hrs after the occlusion and their brains
Table 1. Formulation development for injectable
(S)-roscovitine.
Vehicle Solubility (mg/mL)
Buffer pH 3 1.2
Buffer pH 7.4 0.02
Cremophor EL 5% pH 7.4 1.1
Tween 80 5% pH 7.4 1.0
Hydroxypropyl b-cyclodextrine 10% pH 7.4 0.9
Hydroxypropyl b-cyclodextrine 30% pH 7.4 4.4
Because of the low solubility of (S)-roscovitine at neutral pH, several excipients
were screened in order to increase its solubilization. Excipients presented in this
table are surfactants commercially available for human injectable formulation.
doi:10.1371/journal.pone.0012117.t001
were analyzed by TTC staining. (B, C) Bright field photomicrographs of
adjacent 1 mm thick coronal brain sections of animals ICV- treated with
vehicle- (B) and (S)-roscovitine- (C) and analyzed after 3 hrs of pMCAo.
Ischemic core, hypometabolic zone, and healthy areas were delimited.
(D, E) Core and hypometabolic zone were identified by TTC staining
within the entire brain of vehicle- and (S)-roscovitine- treated animals
and their respective volumes were determined using the ImageJ
software. Total volume of the infarcted regions was determined as the
sum of the core and hypometabolic zone volumes. The corrected
volume of the total infarcted region significantly decreased by 27.7%
and 30.7% in lesioned animals that received (S)-roscovitine adminis-
tered respectively ICV (D)o rI P( E) in comparison to those that received
vehicle only. Note that, while the volume of the core area is comparable
in both vehicle- and (S)-roscovitine- treated animals, the volume of the
hypometabolic zone shows, compared to the vehicle- treated animals, a
35.8% and 38.9% decrease respectively in animals that received (S)-
roscovitine administered ICV (D)o rI P( E). Scale bar: A, B: 9.5 mm
*p ,0.01, t-test.
doi:10.1371/journal.pone.0012117.g001
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the pre-MCAO group (Table S3). Overall animal mortality in
this study was 3%. No significant difference of animal mortality
was observed between the different experimental groups (p=0.51–
0.54, Fisher exact test). In this set of experiment, a slight
difference, although no significant, of the lesion volume was
observed between controls (pooled untreated and vehicle control
groups) and (S)-roscovitine pre-treated group using high dose
(Figure 2E). Furthermore, a significant decrease of 27% in the
total infarct volume was observed between post-treated groups
(pooled (S)-roscovitine post-MCA group) and controls
(Figure 2D). Although not significantly different, our data also
showed that lower doses of (S)-roscovitine (5 and 1 mg/kg/hr)
tend to exhibit a stronger neuroprotective effect that the highest
dose (10 mg/kg/hr) (Figure 2E). (S)-roscovitine dose-dependent
effect was mainly observed in the cortical area of the brain lesion,
where the volume reductions were of 52% and 59% for the two
lowest doses (Figure 2F).
CDKs are involved in (S)-roscovitine mediated
neuroprotective effects
In order to identify (S)-roscovitine targets after stroke, we first
used a model of selective neuronal excitotoxicity using mixed
neuron/glia hippocampal cell cultures and the non- NMDA
agonist kainate (KA) (Figure S2). In the adult rat brain, KA leads
mainly to neuronal death with apoptotic features [29] evocative of
what is generally observed in the penumbra region after ischemic
injury. The neuroprotective effects on KA-induced neuronal death
were evaluated following exposure to the (R) and (S) stereoisomers
of roscovitine, as well as N
6-methyl (R)-roscovitine and O
6-(R)-
roscovitine that are two compounds designed for their inability to
inhibit CDKs [30] (Figure 3A). (R)- and (S)-roscovitine displayed
a significant dose-dependent neuroprotective effect on KA-
induced excitotoxicity (Figure 3A). We also noticed that the (S)-
roscovitine displayed a significantly stronger neuroprotective effect
than the (R) stereoisomer at the 0.5 mM dose in our culture system
(Figure 3A). In contrast, both the kinase inactive N
6-methyl (R)-
roscovitine and O
6-(R)-roscovitine showed no significant neuro-
protective effect even at high concentrations (Figure 3A). In the
adult mouse brain, we used an affinity chromatography approach,
based on roscovitine immobilized on a solid matrix as previously
described [9,30]. Both (S) and (R) stereoisomers, as well as N
6-
methyl-(R)-roscovitine, were immobilized on sepharose beads
(Figure 3B). Analysis of the bound proteins by SDS-PAGE
followed by silver staining and Western blotting showed that (S)-
roscovitine preferentially bound Erk2 and CDK5 in the adult
mouse brain (Figure 3B). Moreover, immobilized (S)- isomer did
not bind PDXK as previously described [30,31], in contrast to
immobilized (R)-roscovitine and N
6-methyl-(R)-roscovitine
(Figure 3B).
CDK5 activity is enhanced following focal cerebral
ischemia and constitutes an in vivo target of (S)-
roscovitine
CDK5 activity was next evaluated in our permanent mouse
stroke model. Our data revealed a significant transient increase of
CDK5 activity in the lesioned ipsilateral hemisphere 3 hrs after
the onset of pMCAo, compared to CDK5 activity of the control
contralateral hemisphere (Figure 4A). At this time point, the level
of p25 protein was also increased in the ischemic hemisphere,
compared to that of the control hemisphere (Figure 4B). These
data suggested that pMCAo induced cleavage of p35 to p25, with
subsequent activation of CDK5/p25 activity. This activation was
detectable as early as 1 hr and as late as 6 hrs post-pMCAo (data
not shown). Ischemic mouse brain CDK5 activity was confirmed
to be inhibited by (S)-roscovitine (IC50 of 0.75 mM) (Figure 4C).
CDK5 activity level was then evaluated in 3 hrs post-pMCAo
brains of animals after systemic administration of (S)-roscovitine.
Our data revealed that the transient increase of CDK5 activity
previously observed in the ischemic ipsilateral brain hemisphere
was significantly prevented by in vivo treatment with (S)-roscovitine
(Figure 4D).
Discussion
Our data shows that the (S) stereoisomer of roscovitine, a CDK
inhibitor, exerts a neuroprotective effect in vivo, after systemic pre-
and post-ischemia administration in experimental stroke models.
Furthermore, we show that this in vivo neuroprotection is mediated
in part by inhibition of CDK5.
It is now accepted that the (R) stereoisomer of roscovitine
displays consistent neuroprotective efficacy in both in vitro and in
vivo models of neuronal death [22,32–34]. Only one stroke study
was however recently reported using a transient model of cerebral
ischemia in rat [22]. In this study, drug was administered in
prevention and through an ICV delivery mode that are not
suitable for stroke patient therapy. Our data revealed that the
neuroprotective effect mediated by systemic administration (IP) of
(S)-roscovitine, the levogyre form of roscovitine, is similar to that
obtained after ICV administration, showing that there is no loss of
neuroprotective effect through systemic administration. Moreover,
we showed that (S)-roscovitine was able to cross brain barrier, in
healthy animals, as already shown for the (R)-roscovitine [24,25].
(S)-roscovitine concentration in the brain was 15% of that
observed in the plasma. Even if it is possible that ruptured BBB
in ischemic animals increased brain roscovitine concentration, our
data suggested that such a concentration fraction was sufficient to
obtain a beneficial effect after stroke. Furthermore, we developed
an injectable formulation of (S)-roscovitine that is suitable for
human therapy. Systemic use of (S)-roscovitine solubilized in
cyclodextrin excipient showed its neuroprotective effect in a
transient model of focal ischemia when the drug is administered
not only prior to the ischemic insult, but also after a 2 hrs time
delayed administration. Furthermore, we showed that the lower
tested (S)-roscovitine doses exhibited stronger neuroprotective
effects than the high dose, suggesting that (S)-roscovitine displayed
a biphasic U-shaped dose-response relationship as frequently
observed in neuroprotection studies [35].
How does (S)-roscovitine protect neurons from excitotoxic








(mg/kg) Sampling time Brain/Plasma
(S)-roscovitine i.v. 20 15 min 0.15 +/2 0.05
i.v. 30 15 min 0.17 +/2 0.07
(S)-roscovitine permeability to the BBB solubilized in 4% HPbCD was examined
after IV administration of the compound to healthy adult rats. (S)-roscovitine
was administered at 2 doses (20 and 30 mg/kg) to the animals (n=2 rats/dose)
and (S)-roscovitine level was determined in the brain and plasma 15 min later.
Approximately 15% of the IV injected (S)-roscovitine was able to cross the BBB
in healthy adult rats.
doi:10.1371/journal.pone.0012117.t002
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ing that (S)-roscovitine neuroprotective effect is CDK- mediat-
ed. CDK5 has been identified as a putative therapeutic target in
ischemia [11]. We confirmed that CDK5/p25 activity is
increased in the ischemic cerebral tissue as previously described
[19,21,36]. Our in vivo data revealed that this increase in CDK5
activity was prevented by the systemic administration of (S)-
roscovitine, supporting the hypothesis that CDK5 is involved in
its neuroprotective effects. It has been shown that (R)-
roscovitine reduced hyperphosporylation of the Tau protein, a
Figure 2. Systemic (S)-roscovitine decreases lesion infarct size after transient focal ischemia in rat when administered prior or 2h15
after the ischemia onset. Two independent blinded studies were performed at Neurokin (A, B) and by MDS Pharma Services (C–F). (A) Scheme of
the experimental protocol performed at Neurokin. Transient focal ischemia was induced in adult rats for 90 min. (S)-roscovitine (n=16 rats) or its
vehicle control (n=18 rats) was administered 15 min prior the occlusion by a IV bolus at one dose (25 mg/kg) and 3 successive SC injections at one
dose (54 mg/kg) performed 15 min prior, 24 and 29 hrs after the occlusion. Rats were analyzed by TTC staining at 48 hrs post-occlusion. (B)
Evaluation of the corrected infarct volumes in this experiment revealed a significant reduction by 30%, 33% and 26% respectively of the total, sub-
cortical, and cortical areas of the brain lesion in presence of (S)-roscovitine administered 15 min prior the ischemia onset. (C) Scheme of the
experimental protocol performed at MDS PS. tMCAo was induced for 120 min. (S)-roscovitine (3 doses tested, n=12 rats per dose) or its vehicle
control (n=13 rats) was administered to tMCAo rats either prior (pre-MCAo) or 135 min after (post-MCAo) the ischemia onset. (S)-roscovitine or
vehicle administration was done by an IV bolus at one dose (25 mg/kg) followed by SC infusion at 3 decreasing doses for 48 hrs (10, 5, and 1 mg/kg).
In addition, untreated control tMCAo animals (n=11 rats) were also prepared. Animals were sacrificed at 72 hrs after the occlusion and their brains
were analyzed by TTC staining. (D) Analysis of the corrected infarct volumes at 72 hrs after a 120 min tMCAo showed no significant difference in total
infarct volume between the vehicle control group and the untreated control group, indicating the absence of effect of the vehicle used in our study.
Therefore, both untreated and vehicle treated groups were pooled in one negative control group. Similarly, (S)-roscovitine- treated groups were
pooled in one group containing the three post-MCAo treated groups only (post- MCAo). A significant decrease of the corrected total infarct volumes
was observed when the pooled negative control was compared to the pooled (S)-roscovitine post-MCAo treated groups. (E) In contrast, no
significant difference was observed between the control groups and each (S)-roscovitine treated group independently of the dose or the
administration time. (F) Although not statistically significant, a dose-dependent beneficial effect of (S)-roscovitine on the lesion volume was observed
mostly on the cortical region of the brain lesion by reducing the volume by 30%, 52% and 58% respectively at 10, 5 and 1 mg/kg/hr, *p,0.01,
** p,0.05, t-test #p,0.01, Mann Whitney test.
doi:10.1371/journal.pone.0012117.g002
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mainly by inhibiting CDK5 [21]. Although CDK5 is undoubt-
edly involved in neuroprotection ,i tm a yn o tb et h eo n l yr e l e v a n t
target. (S)-roscovitine indeed potently inhibits CDK1, CDK2,
C D K 7 ,C D K 9[ 3 7 ] ,a sw e l la sE r k 1 / E r k 2a n dC K 1[ 3 0 ] ,t h a t
play key roles in neuronal development and survival [38].
Increasing evidence indisputably links cell cycle CDKs to the
pathogenesis of stroke [10,11]. Intracerebral administration of
the CDK inhibitor flavopiridol significantly reduced ischemic
damage during focal and global stroke [39,40]. Although these
studies focused on the inhibition by flavopiridol of the cell cycle
CDKs (CDK4 and CDK6), it is important to notice that this
compound also displays a strong inhibition of CDK5 [18,41].
Therefore, a combined inhibition of CDK5 and other kinase
targets by (S)-roscovitine may be essential to provide neuropro-
tection in ischemic tissue.
Is (S)-roscovitine a suitable potential therapeutic agent for
stroke? Because of a slightly better activity of (R)-roscovitine on
CDKs compared to the (S)- isomer [30,37], the (R) stereoisomer
has been most frequently chosen in basic research studies.
Furthermore it has been extensively investigated as a potential
anti-cancer drug (under the names of CYC202 or Seliciclib). It is
currently in late phase 2 clinical trials against non small cell lung
cancer and nasopharyngeal cancer [42]. Despite this fact, we
Figure 3. (S)-roscovitine neuroprotective effects are at least in part mediated by CDKs. (A) Neuroprotective effects of roscovitine analogs
were assessed using an in vitro model of excitotoxicity. Mixed hippocampal cultures were grown for 10 div and exposed to KA (200 mM) for 5 hrs and
to roscovitine stereoisomers or kinase inactive analogs added at the same time as the toxic agent. Beneficial effects of roscovitine on KA-induced
neuronal death were assessed by phase contrast observation and PI-staining. Relative neuronal death (RND) following KA treatment was measured at
different concentrations of (R)-roscovitine [vhcle (n total=322 neurons), 0.5 (n=222), 1 (n=398), 5 (n=392), 10 (n=80), and 15 (n=83) mM], (S)-
roscovitine [vhcle (n=766), 0.05 (n=76), 0.1 (n=272), 0.5 (n=511), 1 (n=528), and 5 (n=479) mM], N
6Me-roscovitine [vhcle (n=326), 0.5 (n=199), 1
(n=163), and 5 (n=173) mM], and O
6-roscovitine [vhcle (n=391), 0.5 (n=174), 1 (n=180), 5 (n=240), and 50 (n=75) mM]. While both (R) and (S)
stereoisomers displayed significant dose-dependent beneficial effect on KA-induced neuronal death, the kinase- inactive roscovitine analogs, N
6-
methyl-(R)-roscovitine and O
6-(R)-roscovitine, did not exhibited any neuroprotective effect in vitro. Note the significantly increased neuroprotective
activity of (S)-roscovitine compared to the (R) stereoisomer at 0.5 mM. (B) Affinity chromatography purification of roscovitine targets in the adult rat
brain. Total brain extract (500 mg) of one healthy mouse was loaded on immobilized (S)-, (R)-, and N
6-methyl-(R)-roscovitine (N6Me), as well as on
ethanolamine beads (control without inhibitor). The beads were extensively washed and the bound proteins analyzed by SDS-PAGE followed by silver
staining (left) and Western blotting (right) against Erk1/2, PDXK, and CDK5. Note that, as previously described in [30,31], only N
6-methyl-(R)-roscovitine
and (R)-roscovitine bind pyridoxal kinase (PDXK) whereas Erk2 and CDK5 bind to both (S) and (R) stereoisomers of roscovitine but not to N
6-methyl-
(R)-roscovitine. * p,0.01 ** p,0.05, t-test.
doi:10.1371/journal.pone.0012117.g003
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tective efficacy than the (R) isomer in our culture system. (S)-
roscovitine displays significant neuroprotective efficacy in both
permanent and transient focal ischemia models in rodent. Besides,
(S)-roscovitine significantly decreased the total infarct volume
when administered after the ischemia onset, although the precise
therapeutic time window still needs to be studied. Finally, we show
that (S)-roscovitine neuroprotective efficacy is observed following
not only ICV but also systemic administration. More recently, it
has been shown that (R)-roscovitine attenuates cell cycle activation
in glial cells, therefore reducing glial scar formation and microglial
activation [22,23]. Although anti-inflammatory properties of the
(S) stereoisomer of roscovitine remain to be demonstrated, all these
observations strongly support a multimodal action for these
compounds.
In conclusion, our results strongly support the idea that systemic
administration of (S)-roscovitine reduces brain damage after
cerebral ischemia in part through a CDK5 mechanism. Roscov-
itine acts, on different cell types (neurons and glia) and through
various mechanisms: anti-apoptotic, anti-excitotoxic, and possibly
anti-inflammatory pathways. Our study revealed that (S)-roscov-
itine successfully meets 7 over the 10 criteria recommended by the
STAIR criteria [8]. Complementary preclinical studies therefore
need still to be addressed, such as long term studies of (S)-
roscovitine neuroprotective effect, evaluation of its beneficial
activity on animal behavior, and association with thrombolytic
agent such as rt-PA. Our findings provide however encouraging
support for the further development of CDK inhibitors as
therapeutic drugs to reduce the neurodegeneration associated
with stroke.
Figure 4. (S)-roscovitine inhibits the increase of CDK5 activity in 3 hrs pMCAo mouse brain. (A) CDK5 activity was evaluated in total
mouse brain extracts after 1, 3, or 24 hrs of pMCAo. Both contra- (non-ischemic) and ipsi- (ischemic) lateral hemispheres were analyzed. CDK5 activity
was assayed after purification by immunoprecipitation as described in the material and methods section. CDK5 activity was significantly increased in
the ipsi-lateral hemisphere 3 hrs after the occlusion. (B) The amount of active CDK5/p35 or p25 complexes was estimated after purification on (S)-
roscovitine beads (500 mg/chromatography) by SDS-PAGE followed by Western blotting using anti-CDK5 and anti-p35/p25 antibodies. The p25 band
intensity in the ipsi (ischemic)-lateral hemispheres is increased after occlusion with a maximum at 3 hrs (values correspond to the percentage of
control intensity and were normalized using the CDK5 band intensity which remained constant). (C) CDK5 activity purified from mouse brain was
inhibited by (S)-roscovitine with an IC50 of 0.75 mM. (D) The increase of CDK5 activity in 3 hrs post-pMCAo brain was prevented by in vivo treatment
with (S)-roscovitine. Three different mice were treated by IP injection of (S)-roscovitine and sacrificed 3 hrs post-pMCAo. The significant difference
between CDK5 activities detected in contra- and ipsi-lateral hemispheres of vehicle control treated animals was not observed when the animals
received (S)-roscovitine treatment. ** p,0.05, t-test.
doi:10.1371/journal.pone.0012117.g004
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Drugs
Both (R) and (S) stereoisomers of roscovitine were studied in this
study (Figure 5A, B) [37]. Two compounds designed for their
inability to inhibit CDKs, N
6-methyl (R)-roscovitine and O
6-(R)-
roscovitine, were also used (Figure 5A, B) [30].
Animals
P60 male C57 b/6 mice (20–25 g; Janvier Breeding Center),
P60 male Sprague Dawley (SD) rats (280–320 g; Janvier Breeding
Center or Harlan Inc) were housed under controlled standard
conditions (diurnal lighting conditions with food and water
available ad libitum). Mice were fasted the day before the surgery.
Animal experimentation performed at Neurokin (pMCAo on
C57b/6 mice and tMCAo on SD rats) was conducted in respect to
the European Communities Council Directive (86/609/EEC), to
the French Department of Agriculture (license n
o 13.343 to BM),
and to the local Veterinary Authorities (license n
o A 13 055 19 to
Institut de Neurobiologie de la Me ´diterrane ´e). No ethical
committee approval was requested for these experiments because
such authorization is not required in France. Animal experimen-
tation performed at MDS Pharma Services (tMCAo on SD rats)
was conducted in compliance with the study protocol, current
MDS PS SOPs and adhered to regulations outlined in the USDA
Animal Welfare Act Act 9 CFR Parts 1–3 (Federal Register 39129,
July 22, 1993) and the conditions specified in the Guide for the
Care and Use of Laboratory Animals (ILAR Publication 1996,
National Academy Press). This protocol was reviewed and
approved by MDS Pharma Services’ Institutional Animal Care
and Use Committee (IACUC).
IACUC PRF Number: S0001 03-25-07
IACUC Protocol Amendment #: S08153 (AA76553)
IACUC Approval date: 20-Aug-2008
IACUC Protocol Amendment #: S08153 (AA76553), Amend-
ment 2
IACUC Approval date: 09-Dec-2008
No alternative test systems were identified as replacement for
the use of live animals in all these in vivo studies.
Injectable (S)-roscovitine formulation
The solubilization of (S)-roscovitine was studied using different
surfactants commercially available for human injectable formula-
tion. These excipients were Polysorbate 80 (Tween 80; Merck),
Cremophor EL (BASF), and hydroxypropyl b-cyclodextrin
(HPbCD; Sigma). Briefly, an excess amount of (S)-roscovitine
was shaken in a precise volume of each excipient for 24 hrs at
20uC. The supernatant was isolated and the quantity of solubilized
(S)-roscovitine analyzed by HPLC, according to Drugabilis
S.A.R.L. (Chatenay Malabry, France) procedures.
Blood brain barrier permeability
SD adult rats received intravenous injection of (S)-roscovitine
solution (HPbCD 30% pH 7.4) at 2 doses (20 and 30 mg/kg; n=2
rats/dose). Dosed animals were sacrificed at 15 min after the end
of the intravenous injection. Blood were collected through the
retro-orbital sinus using a capillary tube. Animals were then
perfused with saline solution into the heart to extract the
maximum blood sample from the brain. Brain was collected,
and homogenized. Both plasma and brain samples were analyzed
using LC/MS/MS determination, according to ADME-Bioana-
lysis (Vergeze, France) procedures.
Permanent middle cerebral artery occlusion, pump
implantation and drug administration in mice
Permanent occlusion of the middle cerebral artery (pMCAo)
was performed on P60 male C57 b/6 mice according to the
previously described protocol [26] modified from [27]. Briefly,
animals were anesthetized intraperitoneally with chloral hydrate
(500 mg/kg). Coagulation of the left MCA was performed with a
bipolar diathermy. During the surgical procedures, animals were
maintained at 37uC using a temperature retro-controlled heating
pad (Harvard Apparatus) and under a heating lamp until full
recovery. Animal body temperature and glucose concentration of
tail vein blood were recorded 3 times during the surgery: prior to
surgery, immediately after the occlusion and at 3 hrs post-
occlusion right before the sacrifice. Animals were sacrificed 1, 3,
and 24 hrs after the occlusion either by cervical dislocation or by
intracardiac perfusion with 4% PFA.
Scheme of the experimental procedures is shown in Figure 1A.
For intracerebroventricular administration of drug, (S)-roscov-
itine at a concentration of 50 mM in DMSO was diluted to
500 mM into Krebs-Ringer’s solution (pH 7.4) containing 0.01%
Evans blue. Drug (n=5 mice) or its vehicle control (n=5 mice)
were administrated to the animals through infusion into the
lateral ventricle (coordinates antero-posterior=0.0, later-
al=20.8, depth=2.2; according to Bregma) using micro-osmotic
pumps (1 ml/hr; Alzet model 1003D) starting 48 hrs before the
occlusion. For intraperitoneal (IP) administration mode, (S)-
roscovitine at an initial concentration of 10 mM in 0.05 M HCl
were diluted in 0.05 M HCl to 25 mg/kg (pH 1.5). 0.05 M HCl
was used for the vehicle-treated animals. Drug (n=5 mice) or its
vehicle control (n=5 mice) were administrated to the animals
through IP injection (250 ml) at 15 min before and 1 hr after
pMCAo.
Figure 5. Structure of roscovitine analogs used in this study.
(A) Structure of (R)- and (S)- stereoisomer of roscovitine, as well as N
6-
methyl (R)-roscovitine and O
6-(R)-roscovitine that are two compounds
designed for their inability to inhibit CDKs [30] (B)I C 50 values (in mM)
previously described for these compounds [30,31]. nd: not determined.
doi:10.1371/journal.pone.0012117.g005
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drug administration in rats
Animals were anesthetized with gaseous isofluorane. Body
temperature was monitored with a rectal temperature probe and
maintained with a heating pad at approximately 37uC throughout
experiment. An incision was made in the scalp and the right
temporal-lateral portion of the skull was exposed. A miniature
plastic probe holder was then fixed to the skull with Super Glue to
allow placement of a laser-Doppler probe directly over a region of
the cortex supplied by the middle cerebral artery. CBF was
continuously recorded by Laser Doppler flowmetry during a
period covering induction of cerebral ischemia (from 8 to 12 min
before- to 10 min after- the occlusion). The mean CBF value was
calculated before surgery (a control period lasting 10 min) and
after MCAo (an ischemic period lasting 5 min after the occlusion).
The percentage of CBF drop was calculated as follow: [1-(mean
CBF during ischemic period/mean CBF during control period)]
x 100.
Transient focal cerebral ischemia (90 or 120 min) was
performed as previously described [43]. Briefly, the right common
carotid artery (CCA), the internal carotid artery (ICA), and the
external carotid artery (ECA) were exposed through a midline
incision of the neck. The pterygopalatine artery was occluded. A
5.0 prolene filament suture, treated with a glue coating to enlarge
the diameter tip (375 mm) was used as an occluder. The occluder
was inserted through a small incision into the ECA and was gently
advanced into the ICA, until a drop in CBF of 75% or greater
associated with a slight thread progression resistance was observed.
Animals that did not show a CBF drop of 75% or greater at this
point were immediately removed from the study and humanely
euthanized. Rats recovered from anesthesia and returned to their
home cages. Ninety minutes (Neurokin study) or 120 min (MDS
PS study) later, rats were re-anesthetized and the occluder
removed to allow reperfusion. Animal body temperature and
glucose concentration of tail vein blood were measured 3 times
during the surgery: prior to surgery, immediately after the
occlusion, and immediately after reperfusion. Animals were
sacrificed either at 48 hrs (Neurokin study) or 72 hrs (MDS PS
study) after occlusion by cervical dislocation.
Schemes of the experimental procedures are shown in
Figures 2A, C. For experiments done at Neurokin (Figure 2A),
(S)-roscovitine (n=16 rats) or vehicle (n=18 rats) was injected into
the animals through a IV bolus (25 mg/kg in HPbCD 30%,
pH 7.4) followed by 3 successive SC injections (54 mg/kg in saline
HCl 50 mM, pH 1.5) performed 15 min before and at 24 and
29 hrs post-occlusion. For experiments performed at MDS
Pharma Services (Figure 2C), drug (n=11–12 rats) or vehicle
(n=13 rats) was administered through a bolus IV (25 mg/kg in
HPbCD 30%, pH 7.4) followed by immediate SC infusion for
48 hrs, and performed either at 15 min prior or 2 hrs 15 min after
the occlusion. Several drug doses were tested for the SC infusion
(10, 5, and 1 mg/kg in saline HCl 50 mM, pH 1.5). Animal
treatments were performed in a blind manner in both tMCAo
studies.
2, 3, 5-triphenyl tetrazolium chloride (TTC) staining and
evaluation of neuronal death
One or two mm-thick coronal sections were prepared from
freshly dissected brains, stained at 37uC in solution of 1% 2,3,5-
TTC (Sigma) in 0.9% saline for 10 min, and fixed overnight with
4% PFA. To measure brain infarct, images from the stained
coronal sections were captured using a digital camera and
analyzed with the ImageJ (NIH) image processing software. In
pMCAo mouse brains, both core and hypometabolic zone were
delineated using the ImageJ free-hand tool for every 1 mm thick-
section, and their volumes determined after calibration using the
software. Total area volumes were determined as the addition of
the volume of both core and hypometabolic zone. In tMCAo rat
brains, total, cortical, and subcortical volumes of the lesion were
calculated on 2 mm thick- TTC stained sections either using the
ImageJ software as previously described or a computerized image
analysis system (Simple PCI; Compix Inc.). The infarct volumes
were captured as actual volumes, and then corrected to
compensate for the presence of brain swelling in the infarcted
hemisphere. A correction factor was calculated by dividing the
volume of the contralateral hemisphere by the ipsilateral
hemisphere. Infarct volumes were then multiplied by this
correction factor to obtain edema- corrected infarct volumes.
E18 mixed hippocampal cells, pharmacological
treatments and evaluation of neuronal death
Mixed hippocampal cell cultures were prepared from embry-
onic day 18 (E18) Wistar rats as previously described [44] and
grown in vitro for 10 days. Treatments were done by directly
adding KA (200 mM; Sigma), drugs, and/or vehicle (DMSO
0.1%) to the medium and left for 5 hrs. No significant KA-induced
toxic effect was ever detected on glial cells at this concentration
(date not shown). The effects of roscovitine compounds [(R)-, (S)-,
N
6-methyl-(R)-, or O
6-(R)-roscovitine] were determined by adding
different concentrations of the molecules ranging from 0.05 to
50 mM to the medium at the same time as the KA addition. The
cell death marker, propidium iodide (PI; 7.5 mM; Sigma), was
added to the medium at 4 hrs. Neuronal death was evaluated at
5 hrs by combining phase contrast and fluorescent microscopy
observations. Neurons from random and representative fields were
counted at low magnification (4x). At least 5 fields per condition
(number total of neurons exceeding in general 150) were examined
from 3 independent cultures. For every condition in every
experiment, percentage of neuronal death was expressed as the
ratio between PI-positive neurons and the total number of neurons
visualized by phase contrast microscopy. To assess neuroprotec-
tion, relative neuronal death (RND) was calculated in 3
independent cultures and a neuroprotection index (NI) defined
as: RND=(% of neuronal death with KA/roscovitine – % of
neuronal death with roscovitine)/(% of neuronal death with KA -
% of neuronal death with vehicle), and NI=1-RND. By
definition, relative percentage of neuronal death (RND) in KA-
treated culture was 100% and neuroprotection index (NI) was 0%.
Affinity chromatography on immobilized drugs
The preparation of N
6-methyl-(R)-roscovitine and (R) - and (S)-
roscovitine resins was described previously [30,31]. Healthy or
pMCAo mouse brains were freshly dissected, ipsi (ischemic) - and
contra (non-ischemic) - lateral hemispheres isolated and snap
frozen until further use. Tissues were homogenized and sonicated
in homogenization buffer (PY buffer: 60 mM b-glycerophosphate,
15 mM p-nitrophenylphosphate, 25 mM Mops (pH 7.2), 15 mM
EGTA, 15 mM MgCl2, 1 mM DTT, 1 mM Na vanadate, 1 mM
NaF, 1 mM phenylphosphate, 10 mg leupeptin/ml, 10 mg apro-
tinin/ml, 10 mg soybean trypsin inhibitor/ml and 100 mM
benzamidine). Homogenates were centrifuged for 10 min at
14,000 g at 4uC. The supernatant was recovered, assayed for
protein content (Bio-Rad protein assay) and immediately loaded
batch wise on the affinity matrix. Just before use, 10 ml of packed
roscovitine beads were washed with 1 ml of bead buffer (50 mM
Tris pH 7.4, 5 mM NaF, 250 mM NaCl, 5 mM EDTA, 5 mM
EGTA, 0.1% NP-40, 10 mg/ml of leupeptin, aprotinin and
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pended in 600 ml of the same buffer. The tissue extract
supernatant (500 mg total protein) was then added; the tubes were
rotated at 4uC for 30 minutes. After a brief spin at 10,000 g and
removal of the supernatant, the beads were washed 4 times with
bead buffer before addition of 60 ml 2X Laemmli sample buffer.
Following heat denaturation for 3 min. bound proteins were
analyzed by SDS-PAGE and Western blotting or silver staining.
Electrophoresis, Western blotting, and silver staining
Following heat denaturation for 3 min, the proteins bound to
the roscovitine matrix were separated by 10% SDS-PAGE
followed by immunoblotting analysis or silver staining using a
GE Healthcare SDS-PAGE silver staining kit. For immunoblot-
ting, proteins were transferred to 0.45 mm nitrocellulose filters.
These were blocked with 5% low fat milk in Tris-Buffered Saline -
Tween-20, incubated for 1 hr with antibodies and analyzed by
Enhanced Chemiluminescence (ECL, GE Healthcare). The
following antibodies were used: anti-CDK5 (1:500; Santa Cruz
Biotechnology), anti-Erk1/2 (1:4000; Sigma), anti-p35/p25 (1:500;
Santa Cruz Biotechnology), or anti-PDXK (1:500; [30]).
Immunoprecipitation and protein kinase assays
Brain lysates (500 mg) were incubated with 0.8 mg of p35
antibodies (Santa Cruz Biotechnology). The CDK5/p35 and
CDK5/p25 immunocomplexes were washed 4 times with bead
buffer (50 mM Tris pH 7.4, 5 mM NaF, 250 mM NaCl, 5 mM
EDTA, 5 mM EGTA, 0.1% NP-40, 10 mg/ml of leupeptin,
aprotinin and soybean trypsin inhibitor and 100 mM benzamidine)
and one time with buffer C (60 mM b-glycerophosphate, 30 mM
p-nitrophenylphosphate, 25 mM Mops (pH 7.0), 5 mM EGTA,
15 mM MgCl2, 1 mM DTT, 0.1 mM sodium vanadate). The
CDK5 kinase activity was assessed directly on the beads in buffer
C, with 1 mg histone H1/ml, in the presence of 15 mM[ c-
33P]
ATP (3,000 Ci/mmol; 10 mCi/ml) in a final volume of 30 ml.
After 20 min of incubation at 30uC, 20 ml aliquots of supernatant
were spotted onto 2.563 cm pieces of Whatman P81 phospho-
cellulose paper, and, 20 seconds later, the filters were washed four
times (for at least 5 min each time) in a solution of 10 ml
phosphoric acid/liter of water. The wet filters were counted in the
presence of 1 ml ACS (GE Healthcare) scintillation fluid.
Statistical analysis
Results are expressed as mean +/2 SEM. For Gaussian
distributed continuous variable two tailed (one tailed for 2 hrs
tMCAo studies) paired Student’s t-test was used. For non-Gaussian
distributed continuous variables, the nonparametric Mann-Whit-
ney U test was used. The alpha level was set at 0.05.
Supporting Information
Figure S1 A hypometabolic zone is observed 3 hrs after pMCAo
in the adult mouse brain. Adult C57 b/6 mice were submitted to
permanent middle cerebral artery occlusion (pMCAo) and their
brains were analyzed 3 hrs after the occlusion by mitochondrial-
activity TTC, TUNEL or FluoroJade staining. (A) Gray scale
digital pictures of TTC- stained 1 mm- thick coronal sections of an
adult mouse brain 3 hrs after pMCAo. Three areas were
distinguished and delineated based on their white/gray scale
densities: the darker density displaying the lowest score corre-
sponded to the healthy area, the moderate score to the
hypometabolic zone while the lowest density corresponded to
the core. (B) Relative white densities of the core, hypometabolic
zone and healthy areas were quantified using the ImageJ software
on gray-scaled digitalized pictures in 7 independent coronal
sections after 3 hr of pMCAo and TTC staining. In comparison to
the healthy region, the intensity increased by 73% in the
hypometabolic zone and by 204% in the core area. Note the
75% increase of white density between the core and the
hypometabolic zone. (C–E) Bright field (C) and confocal
fluorescent (D. E) photomicrographs of 50 mm thick coronal brain
sections 3 hr after pMCAo labeled either with TUNEL (C) or
FluoroJade B (FJB) (D, E). Section in C was counterstained with
cresyl violet. Note in C that TUNEL-positive cells were identified
in the core but were absent of the hypometabolic zone. In contrast,
FluoroJade B-labeled neurons were found in both core and
hypometabolic zone (D, E). Scale bars: A: 5 mm; C: 100 mm; D,
E: 130 mm* ,#p,0.01 t-test.
Found at: doi:10.1371/journal.pone.0012117.s001 (0.56 MB TIF)
Figure S2 Specific neuronal death induced by excitotoxic KA
on mixed hippocampal cultures. (A–C) Hippocampal cells
isolated from E18 rat embryos and grown in vitro for 10 or 15
days (div) were characterized by immunocytochemistry with cell
type specific antibodies and patch clamp recording. (A) Bright
field photomicrograph of the 10 div cell culture by phase
contrast. (B) Fluorescence confocal photomicrograph of the 10
div culture labeled with GFAP- (red), beta III tubulin- (green),
and O4- (blue) antibodies. Hippocampal cultures contained both
neuronal and glial cell types. (C) Traces showing voltage clamp
recording in whole-cell configuration of neurons grown for 10
(top trace) and 15 (bottom trace) div. Note that 15 div neurons
display large and frequent postsynaptic currents, reflecting a
more mature neuronal network at the latest in vitro stage. (D) A
model of neuronal excitotoxicity was developed using 10 div
mixed hippocampal cultures and KA. Fluorescence photomicro-
graphs of cultures exposed to either vehicle control (left panel) or
200 mM KA (right panel) and labeled with the neuronal anti-beta
III tubulin antibody (top panel) or the cell death marker PI
(bottom panel). Note a decrease in the density of beta-tubulin-
positive neurons and an increase of that of PI-labeled cells in the
KA-treated cultures in comparison to the vehicle-treated cultures.
(E) Relative percentage of beta III tubulin-positive cells in the
culture after vehicle- or KA- treatment. Note about 40% decrease
in the neuronal density in the culture after KA exposure. (F)
Dose-dependent response of neuronal excitotoxicity after a 5 hrs
exposure to either vehicle or different KA concentrations ranging
from 20 to 400 mM. In our cell culture model, treatment with
200 mM KA for 5 hrs was necessary to obtain approximately
50% of neuronal loss. Scale bars: A: 400 mm, B: 475 mm, D:
900 mm*p ,0.01 t-test.
Found at: doi:10.1371/journal.pone.0012117.s002 (0.80 MB TIF)
Table S1 Table summarizing the physiological parameters of
the pMCAo C57 b/6 mice measured at different time points of the
surgical procedures.
Found at: doi:10.1371/journal.pone.0012117.s003 (0.03 MB
DOC)
Table S2 Table summarizing the physiological parameters of
the tMCAo SD rats (Neurokin study) measured at different time
points of the surgical procedures. ** p,0.05, * p,0.01, t-test.
Found at: doi:10.1371/journal.pone.0012117.s004 (0.03 MB
DOC)
Table S3 Table summarizing the physiological parameters of
the tMCAo SD rats (MDS PS study) measured at different time
points of the surgical procedures. ** p,0.05, t-test.
Found at: doi:10.1371/journal.pone.0012117.s005 (0.04 MB
DOC)
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